new COX-2 inhibitor called Bextra (valdecoxib)

January 2002

You'll see a new COX-2 inhibitor called Bextra (valdecoxib).

It'll be co-marketed by Pharmacia and Pfizer...the same companies that market Celebrex (celecoxib).

Bextra is approved for osteoarthritis...rheumatoid arthritis...and dysmenorrhea. It's NOT approved yet for acute pain...but that's likely to change after the company submits additional studies to the FDA.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote